Support for Vaccine: Rotavirus
This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Sudan, Republic of


3. Date of Decision Letter: 11-Jul-19

4. Date of the Partnership Framework Agreement: December 10, 2013

5. Programme title: New Vaccine Support (NVS), Rotavirus, Routine

6. Vaccine type: Rotavirus

7. Requested product presentation and formulation of vaccine:
RV1, 1 dose/plastic tube, liq

8. Programme Duration: 2011-2020

9. Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement, if applicable)

| Programme Budget (US$) | 2011-2018 | 2019 | 2020 | 2021 | 2022 | 2023 | Total
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2011-2018</td>
<td>39,759,514</td>
<td>6,744,500</td>
<td>6,529,500</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>53,033,514</td>
</tr>
</tbody>
</table>

10. Vaccine introduction grant
Not applicable

11. Product switch grant
Not applicable

12. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement, if applicable)

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Gavi funds</th>
<th>2011-2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td></td>
<td>2,908,500</td>
<td>-</td>
</tr>
<tr>
<td>Annual Amounts (US$)</td>
<td>39,759,514</td>
<td>6,744,500</td>
<td>-</td>
</tr>
</tbody>
</table>

13. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

14. Self-procurement: Not applicable

---

1 This is the entire duration of the Programme.
2 This is the total amount endorsed by Gavi for the entire duration of the Programme.
3 This is the total amount approved by Gavi.
15. **Co-financing obligations:**

According to the co-financing policy, the Country falls within the group: Preparatory transition phase

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

<table>
<thead>
<tr>
<th>Type of supplies to be purchased with Country funds in each year</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of vaccine doses</td>
<td>528,000</td>
<td>604,500</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of AD syringes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of re-constitution syringes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Number of safety boxes</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Value of vaccine doses (US$)</td>
<td>1,186,812</td>
<td>1,358,505</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Total co-financing payments (US$) (including freight)</td>
<td>1,221,500</td>
<td>1,398,500</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

16. **Operational support for catch-up campaigns:**

Not applicable

17. **Additional Reporting Requirements:**

To prepare for the annual procurement of vaccines, Country shall submit the following information each year:

- vaccine stock levels including buffer stock, by end of March; *Due dates: March 31, 2020*
- number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. *Due dates: May 15, 2020*
- Countries shall report the actual switch date in the first renewal request following the actual implementation.

In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance. *To be agreed with Gavi Secretariat*

18. **Financial clarifications:**

Country shall provide the following clarifications to Gavi*

*Not applicable*

*Failure to provide the financial clarifications requested may result in Gavi withholding further disbursements.*
19. Other conditions:

Not applicable

On behalf of Gavi

Pascal Bijleveld
Managing Director, Country Programmes a.i.